drugset
drugset / Trial / NCT02756728

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

NCT02756728 ↗

Phase 1/2 Terminated 5 enrolled BioInvent International AB
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and efficacy of administering BI-505 in conjunction with high dose melphalan and stem cell transplantation in multiple myeloma patients.

Timeline

Start
2016-05
Primary completion
2016-12
Completion
2016-12

Outcome

Outcome not reported

Stopped: “Full clinical hold from FDA”

Drugs

EvaluationDrugModalityDoseRoute
Subject BI-505 Monoclonal antibody 10 mg/kg —

Indications

plasma cell myeloma